Pacira Biosciences, Inc. (PCRX)

Over the past six months, Pacira Biosciences' stock price has declined. The stock has experienced a decline of 14.60% in the last six months and a 20.59% decrease in the past month. Between February 3, 2025, and January 30, 2026, the share price declined by 20.23%. Key events include the Q3 2025 earnings report, where EPS beat estimates but revenue missed; Q2 2025 earnings report, where EXPAREL and ZILRETTA sales were reported; an updated FY 2025 earnings guidance, which led to a share price reaction; activist investor pressure from DOMA Perpetual Capital Management LLC; and Q1 2025 financial results, where total revenues and product sales were reported.

Information explicitly detailing the demand seasonality for Pacira Biosciences, Inc.'s products and services is not readily available in the provided search results. The company's financial reports indicate quarterly revenues and sales figures, but do not break down demand fluctuations based on seasonal patterns.

Pacira Biosciences, Inc. is a holding company focused on non-opioid pain management and regenerative health solutions in the United States. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Pacira's mission is to deliver innovative non-opioid pain therapies to transform patients' lives. Its major commercial products include EXPAREL, a long-acting local analgesic; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and the iovera system, a handheld device for drug-free pain control. Pacira is also advancing its pipeline with PCRX-201, a gene therapy vector platform for treating osteoarthritis.

Pacira Biosciences, Inc. is headquartered in Brisbane, California. The company's primary commercial activities are directed towards healthcare practitioners in the United States.

Pacira Biosciences maintains a brand reputation centered on its leadership in non-opioid pain management and regenerative health solutions. The company emphasizes its commitment to delivering innovative therapies and transforming patient lives. Pacira actively promotes the expansion of access to safe and effective non-opioid therapies through education and advocacy. The activist campaign by DOMA Perpetual Capital Management LLC in January 2026, which challenged the company's capital allocation and oversight and pushed for a potential sale process, could be seen as an event impacting its corporate reputation among investors.

Pacira Biosciences, Inc. has significant institutional ownership, with 480 institutional owners and shareholders holding a total of 58,301,224 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Doma Perpetual Capital Management LLC, Dimensional Fund Advisors Lp, Renaissance Technologies Llc, D. E. Shaw & Co., Inc., State Street Corp, and Balyasny Asset Management Llc. Institutional ownership accounts for approximately 97.19% of the company, with individuals holding about 3.09%.